THE SYDNEY MULTICENTER STUDY OF PARKINSONS-DISEASE - A RANDOMIZED, PROSPECTIVE 5-YEAR STUDY COMPARING LOW-DOSE BROMOCRIPTINE WITH LOW-DOSE LEVODOPA-CARBIDOPA
Ma. Hely et al., THE SYDNEY MULTICENTER STUDY OF PARKINSONS-DISEASE - A RANDOMIZED, PROSPECTIVE 5-YEAR STUDY COMPARING LOW-DOSE BROMOCRIPTINE WITH LOW-DOSE LEVODOPA-CARBIDOPA, Journal of Neurology, Neurosurgery and Psychiatry, 57(8), 1994, pp. 903-910
149 previously untreated patients with Parkinson's disease were recrui
ted over a three year period and randomly allocated to either low dose
levodopa-carbidopa (less than or equal to 600/150 mg/day) or low dose
bromocriptine (less than or equal to 30 mg/day). A five year follow u
p is reported on the 126 patients who completed the dose titration and
who have not developed features of atypical Parkinsonism. Levodopa-ca
rbidopa in low dosage adequately controlled symptoms in most patients
and delayed the appearance of dyskinesia and end of dose failure for a
bout two years longer than conventional doses. Only a few patients cou
ld be managed for more than one year on low dose bromocriptine alone;
these patients had mild disease and asymmetric signs. Patients randomi
sed to bromocriptine did not develop dyskinesia or troublesome end of
dose failure until levodopa-carbidopa was added. The prevalence of dys
kinesia in this group was lower than in patients given levodopa-carbid
opa alone. The prevalence of end of dose failure was similar in the tw
o randomisation groups once levodopa was introduced.